DEINOVE AND GREENTECH ANNOUNCE THE LAUNCH OF HEBELYS®,
THE FIRST COSMETIC ACTIVE INGREDIENT RESULTING FROM THEIR COLLABORATION
- HEBELYS® is a natural active ingredient produced by the fermentation of Sphingomonas, a bacterium belonging to the DEINOVE proprietary strain library.
- Various tests have demonstrated its ability to preserve youthful skin through its action on various aging factors and, in particular, on a protein involved in the process of cellular senescence.
- This new active ingredient will be presented during the In-Cosmetics trade show in Amsterdam (April 17-19).
Montpellier, April 16, 2018 (7:30 am CEST) - DEINOVE (Euronext Growth Paris: ALDEI), a biotechnology company that discovers, develops and produces compounds with high added value from rare bacteria, and GREENTECH, a major player in the production and distribution of active ingredients derived from biotechnology, today announced the launch of HEBELYS®, the first anti-aging active ingredient resulting from the collaboration launched in March 2017[1].
HEBELYS® will be presented in the GREENTECH booth at the In-cosmetics Global trade show, which will take place in Amsterdam from April 17 to 19, 2018.
This anti-aging active ingredient is obtained by fermentation of a Sphingomonas bacterium, a rare microorganism coming from the DEINOVE strain library.
Through tests, HEBELYS® demonstrated its ability to preserve youthful skin, acting on different parameters: protection against oxidation, stimulation of collagen, elastin, and fibrillin synthesis. HEBELYS® has, in particular, a significant and proven action on the expression of the p16 IINK4A protein, a key factor of premature cellular aging.
Under the effect of HEBELYS®, the skin is protected, regaining density, suppleness, and elasticity: younger-looking.
HEBELYS® is the first active ingredient resulting from the collaboration between DEINOVE and GREENTECH, fruit of the alliance of complementary skills: DEINOVE selected the strain, developed the production process to achieve optimal fermentation performances, and supervised the in vitro tests intended to characterize the extract; GREENTECH developed the formulation process, and validated the stability and the safety, as well as the efficiency, by additional ex vivo tests.
HEBELYS® will be marketed effectively by GREENTECH.
Jean-Yves Berthon, CEO of GREENTECH, stated: "This first collaboration is a real success. HEBELYS® is a truly great active ingredient, fully in line with our catalog and our ambition to offer the cosmetic industry high-tech active ingredients."
Emmanuel PETIOT, CEO of DEINOVE added: "The joint work of both teams has been very rewarding. We are proud to have responded to GREENTECH's expectations in terms of innovation and achieved a commercial product so quickly. We intend to continue in this direction."
ABOUT GREENTECH
A pioneer in plant biotechnology when created in 1992, GREENTECH develops and produces for the cosmetic, pharmaceutical and nutraceutical sectors, high-tech active ingredients originating from the deep mechanisms of plants, algae, micro-algae and micro-organisms drawn from across the world.
Containing over 100 active ingredients and 3 000 extracts, GREENTECH's portfolio meets all expectations and needs of the skin, whatever the functionality or the age.
The GREENTECH group, with its 3 companies - GREENTECH, GREENSEA and BIOVITIS - has 3 subsidiaries in Germany, USA, and Brazil and is present on all continents and more than 30 countries across the world thanks to a network of local distributors.
Contacts
| Jean-Yves Berthon CEO Tel: +33 (0)4 73 33 99 00 [email protected] | Edith Filaire Scientific Director Tel: +33 (0)4 73 33 99 00 [email protected] |
ABOUT DEINOVE
DEINOVE (Euronext Growth Paris: ALDEI) is a biotech company that discovers, develops and produces high added-value compounds from rare microorganisms for use in the fields of health, nutrition and cosmetic markets. To do so, DEINOVE draws on two key assets:
- a unique library of 6,000 rare or unexploited bacterial strains;
- a metabolic and fermentation engineering platform capable of leveraging these natural "micro-factories" to turn them into new industrial standards.
Based in Montpellier, DEINOVE employs approximately 55 employees and has nearly 130 international patents. The Company has been listed on Euronext Growth since April 2010.
Contacts
| Emmanuel Petiot CEO Tel: +33 (0)4 48 19 01 28 [email protected] | Coralie Martin Communication, Marketing and Investor Relations Tel: +33 (0)4 48 19 01 60 [email protected] |
| ALIZE RP, Press Relations Caroline Carmagnol / Aurore Gangloff Tel: +33 (0)1 44 54 36 66 [email protected] |
| www.deinove.com | twitter.com/Deinove | linkedin.com/company/deinove |
[1] Press release of March 27, 2017
Attachment


Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves
FTC Questions Apple News Over Alleged Bias Against Conservative Media
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
How Marco Pharma International Preserves German Homeopathic Traditions in America
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 



